About panitumum ab
EGFR-blocking monoclonal antibody
Used for
- Treats RAS wild-type metastatic colorectal cancer, alone or with certain chemotherapy.
Usual adult dose
6 mg/kg by intravenous infusion every 14 days; dose and treatment depend on the cancer regimen.
Common side effects
- Acne-like rash, dry or itchy skin, nail problems
- Diarrhea, nausea, abdominal pain
- Low magnesium and other electrolyte changes
- Infusion reactions and eye inflammation
Important warnings
- Only for tumors confirmed as RAS wild-type; ineffective and potentially harmful with RAS mutations.
- Can cause severe skin reactions, infections, and rarely life-threatening skin complications.
- Monitor magnesium, calcium, and potassium during treatment and after stopping.
- Stop infusion and seek urgent care for breathing difficulty or severe allergic reaction.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for two months afterward.
Breastfeeding
Avoid breastfeeding during treatment and for two months after the final dose.
Interactions
- Combining with oxaliplatin-based chemotherapy is not recommended for RAS-mutant or unknown-status tumors.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.